Abstract：Objective To study the clinical features of children with Mycoplasma pneumoniae pneumonia (MPP) and peripheral lymphocytopenia. Methods A total of 310 MPP children who were hospitalized and underwent bronchoalveolar lavage from June 2018 to June 2019 were enrolled and divided into two groups: simple MPP group with 241 children (without peripheral lymphocytopenia) and MPP + peripheral lymphocytopenia group with 69 children. The two groups were compared in terms of clinical data and treatment outcome. Results Compared with the simple MPP group, the MPP + peripheral lymphocytopenia group had significantly longer duration of fever and length of hospital stay and significant increases in C-reactive protein, lactate dehydrogenase, and Mycoplasma pneumoniae DNA copies in bronchoalveolar lavage fluid (P < 0.05). Compared with the simple MPP group, the MPP + peripheral lymphocytopenia group had significantly higher incidence rates of intrapulmonary consolidation, extrapulmonary complications, and serious lesions under bronchoscopy (erosion or sputum bolt) and a significantly higher proportion of patients with severe MPP (P < 0.05). Conclusions Children with MPP and peripheral lymphocytopenia tend to have more severe immunologic injury. Peripheral blood lymphocyte count may be used to evaluate the severity of MPP.
PENG Li,ZHONG Li-Li,HUANG Zhen et al. Clinical features of children with Mycoplasma pneumoniae pneumonia and peripheral lymphocytopenia[J]. CJCP, 2021, 23(1): 74-77.
Leung AKC, Wong AHC, Hon KL. Community-acquired pneumonia in children[J]. Recent Pat Inflamm Allergy Drug Discov, 2018, 12(2):136-144.
[2]
Bajantri B, Venkatram S, Diaz-Fuentes G. Mycoplasma pneumoniae:a potentially severe infection[J]. J Clin Med Res, 2018, 10(7):535-544.
[3]
Saraya T, Kurai D, Nakagaki K, et al. Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications[J]. Front Microbiol, 2014, 5:410.
[4]
Guo L, Liu F, Lu MP, et al. Increased T cell activation in BALF from children with Mycoplasma pneumoniae pneumonia[J]. Pediatr Pulmonol, 2015, 50(8):814-819.
Saraya T. Mycoplasma pneumoniae infection:basics[J]. J Gen Fam Med, 2017, 18(3):118-125.
[8]
Bodhankar S, Sun X, Woolard MD, et al. Interferon gamma and interleukin 4 have contrasting effects on immunopathology and the development of protective adaptive immunity against Mycoplasma respiratory disease[J]. J Infect Dis, 2010, 202(1):39-51.
Bajantri B, Toolsie O, Venkatram S, et al. Mycoplasma pneumoniae pneumonia:walking pneumonia can cripple the susceptible[J]. J Clin Med Res, 2018, 10(12):891-897.
[11]
Obirikorang C, Quaye L, Acheampong I. Total lymphocyte count as a surrogate marker for CD4 count in resource-limited settings[J]. BMC Infect Dis, 2012, 12:128.
[12]
Stebbing J, Sawleshwarkar S, Michailidis C, et al. Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people[J]. Postgrad Med J, 2005, 81(959):586-588.
[13]
Zhang Y, Mei S, Zhou Y, et al. Cytokines as the good predictors of refractory Mycoplasma pneumoniae pneumonia in schoolaged children[J]. Sci Rep, 2016, 6:37037.
[14]
Jeong JE, Soh JE, Kwak JH, et al. Increased procalcitonin level is a risk factor for prolonged fever in children with Mycoplasma pneumonia[J]. Korean J Pediatr, 2018, 61(8):258-263.
